Emmanuelle Waubant (United States of America)

UCSF Neurology
Emmanuelle L. Waubant, MD, PhD, received her medical degree at the University of Lille, France. She then trained in France as well as at the University of California, San Francisco (UCSF) in adult neurology, neuroimmunology and MS clinical research. She is currently Professor of Neurology and Pediatrics at UCSF. She has served as the Race to Erase MS medical director since 2001. She also directs the Regional Pediatric MS Center at UCSF and is the secretary for the Americas Committee on Treatment and Research in MS. Dr. Waubant serves or has served on the clinical care, fellowship and research grant review, and research programs advisory committees of the National MS Society. She is the Chair of the Clinical Trial Task Force of the International Pediatric MS Study Group and a Steering Committee member of the US Pediatric MS Network and International Pediatric MS Study Group. She also directs translational research projects and mentors junior investigators on various clinical, research and career development aspects in the field of MS and related diseases. In 2018, Dr. Waubant started an international consortium (international Women in MS) to foster community spirit among clinicians and scientists from all over the world, promote diversity in professional organizations and mentor junior women in the field of MS. Dr. Waubant’s specific interests include the translation of promising agents from the bench to bedside to advance patients’ care, and risk factors for MS susceptibility and disease modification in pediatric and adult MS.

Author Of 2 Presentations

PEDIATRIC MS

Session Type
Teaching Course
Date
06.10.2021, Wednesday
Session Time
17:10 - 18:40
Room
Teaching Course A
Lecture Time
17:10 - 17:33
Presenter
  • Emmanuelle Waubant (United States of America)
Scientific Session: MT (Main Topics)

PAEDIATRIC MS

Session Type
Scientific Session: MT (Main Topics)
Date
03.10.2021, Sunday
Session Time
17:10 - 18:40
Room
Main Topic A
Lecture Time
17:33 - 17:56
Presenter
  • Emmanuelle Waubant (United States of America)

Abstract

Abstract Body

Pediatric MS (i.e. disease onset before 18 years) shares many characteristics with adult-onset MS. However, children with MS have higher relapse and new MRI lesion rates than adults. They tend to have more severe relapses, with better recovery, but still develop disability at a younger age than adult-onset MS. Pediatric MS has the potential for irreversible central nervous system injury especially as it is still maturing.

Differential diagnoses include ADEM, NMO and MOG-associated disease, among others.

Very few drugs have been formally tested in that age group limiting the availability of safety and efficacy data. Treatment compliance in teenagers can be a particular problem. Discussing treatment options with teenagers and understanding their expectations and preferences may help pick a treatment that will have a better patient adherence. Over the past 10 years, physicians caring for patients with pediatric MS have increasingly used early intervention to limit disability progression and more aggressive treatment options. Interferons and glatiramer acetate have been the usual initial treatment choices for MS in children as open-label studies have shown they are safe. Other drugs such as natalizumab, fingolimod, fumaric acid, or rituximab/ocrelizumab are newer options. Limited information is available from retrospective studies regarding the safety and efficacy of these drugs in children except for fingolimod and teriflunomide that were studied in a randomized controlled trials in patients 10-17 years of age. Several ongoing trials are investigating the use of dimethyl fumarate and ocrelizumab in pediatric MS and will aid future treatment decisions including short-term safety information.

Hide

Presenter of 2 Presentations

PEDIATRIC MS

Session Type
Teaching Course
Date
06.10.2021, Wednesday
Session Time
17:10 - 18:40
Room
Teaching Course A
Lecture Time
17:10 - 17:33
Presenter
  • Emmanuelle Waubant (United States of America)
Scientific Session: MT (Main Topics)

PAEDIATRIC MS

Session Type
Scientific Session: MT (Main Topics)
Date
03.10.2021, Sunday
Session Time
17:10 - 18:40
Room
Main Topic A
Lecture Time
17:33 - 17:56
Presenter
  • Emmanuelle Waubant (United States of America)

Abstract

Abstract Body

Pediatric MS (i.e. disease onset before 18 years) shares many characteristics with adult-onset MS. However, children with MS have higher relapse and new MRI lesion rates than adults. They tend to have more severe relapses, with better recovery, but still develop disability at a younger age than adult-onset MS. Pediatric MS has the potential for irreversible central nervous system injury especially as it is still maturing.

Differential diagnoses include ADEM, NMO and MOG-associated disease, among others.

Very few drugs have been formally tested in that age group limiting the availability of safety and efficacy data. Treatment compliance in teenagers can be a particular problem. Discussing treatment options with teenagers and understanding their expectations and preferences may help pick a treatment that will have a better patient adherence. Over the past 10 years, physicians caring for patients with pediatric MS have increasingly used early intervention to limit disability progression and more aggressive treatment options. Interferons and glatiramer acetate have been the usual initial treatment choices for MS in children as open-label studies have shown they are safe. Other drugs such as natalizumab, fingolimod, fumaric acid, or rituximab/ocrelizumab are newer options. Limited information is available from retrospective studies regarding the safety and efficacy of these drugs in children except for fingolimod and teriflunomide that were studied in a randomized controlled trials in patients 10-17 years of age. Several ongoing trials are investigating the use of dimethyl fumarate and ocrelizumab in pediatric MS and will aid future treatment decisions including short-term safety information.

Hide